Pathology & Laboratory Medicine Update on COVID-19 Testing
Below is the most recent announcement regarding COVID-19 from the Department of Pathology & Laboratory Medicine.
Updated Provider Guidance on Serologic Testing for SARS-CoV-2
The Clinical Immunology and Clinical Core labs at the Hospital of the University of Pennsylvania have discontinued serologic testing for SARS-CoV-2. The two tests that were previously performed, COVID-19 (SARS-CoV-2) antibodies (Anti-Nucleocapsid IgG Antibody) and SARS-CoV-2 Serology, antibodies, immunoassay (RBD assessment), are no longer available as in-house assays.
read moreNew High Sensitivity Troponin Assay at UPHS

High Sensitivity Troponin, a new, clinically validated assay that allows for more rapid and accurate detection of myocardial injury, was launched throughout UPHS, highlighting our goal of a systemic integration at a multi-entity and multidisciplinary level.
read moreWang Lab Develops SARS-CoV-2 Rapid Antigen Assay With High Sensitivity
Antigen test detects small loads of SARS-CoV-2 with sensitivity as high as a PCR test and moves toward POCT application.
Read moreFemtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking
Read moreProject Quaker Rolled Out for On-Campus COVID-19 Testing
Large-scale COVID-19 screening program known as Project Quaker is being rolled out across campus with the goal of conducting 40,000 saliva-based tests each week.
Read more